June 26, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or ...
Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an ...
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Swiss biopharmaceutical company Idorsia has appointed Roland Wandeler as chief executive officer, effective October 1, as it looks to build on a recent financial turnaround and accelerate growth ...
Net revenue of CHF 59 m in Q1 2025 resulted from QUVIVIQ product sales (CHF 25 m), product sales to partners (CHF 1 m), and contract revenues (CHF 32 m), comprising a one-off exclusivity fee of CHF 32 ...
The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and ...
(RTTNews) - Viatris Inc. (VTRS) and Idorsia Ltd announced a substantial global research and development collaboration. Under this agreement, Viatris will gain exclusive global development and ...
(RTTNews) - Idorsia Ltd (IDIA.SW) announced the publication of pivotal Phase 3 MODIFY study results and its open-label extension (OLE) in Nature Communications. The study evaluated lucerastat, an oral ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Swiss drugmaker Idorsia said on Monday it has received the U.S. Food and Drug Administration's approval for its ...
Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO - effective October 1, 2026 - an experienced biopharmaceutical executive combining scientific expertise with business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results